Imatinib and Clarithromycin (Klamer 500 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibition can reduce imatinib metabolism and increase systemic exposure.
Clinical significance and safety
Klamer 500 mg contains clarithromycin, a systemic strong CYP3A inhibitor. It may raise imatinib exposure and increase treatment-related toxicity. The prescribing team should review alternatives or a label-directed monitoring and adjustment plan. Do not alter either prescription independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.